Metraipolis › archive › dc_19eb5f8a5da0

Immune checkpoint inhibitors continuation beyond progression as second-line treatment for extensive-stage small-cell lung cancer: a real-world, multicenter… — Europe PMC PMID:41306967

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41306967
DOI
10.3389/fimmu.2025.1666373
License (as archived)
solo-consultazione
Archived
2026-11-08T16:11:14.897Z
SHA-256 of the archived text
650759f27c4353401781388f9cd42267cf4ce2f35d35959b80cd78d350163fce
Stable URL of this page
https://metraipolis.com/documento/dc_19eb5f8a5da0

How to cite

Immune checkpoint inhibitors continuation beyond progression as second-line treatment for extensive-stage small-cell lung cancer: a real-world, multicenter… — Europe PMC PMID:41306967 — Europe PMC (en), https://europepmc.org/article/MED/41306967 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_19eb5f8a5da0 (Metraipolis archive dc_19eb5f8a5da0, sha256 650759f27c4353401781388f9cd42267cf4ce2f35d35959b80cd78d350163fce)
BibTeX
@misc{dc19eb5f8a5da0,
  title = {Immune checkpoint inhibitors continuation beyond progression as second-line treatment for extensive-stage small-cell lung cancer: a real-world, multicenter… — Europe PMC PMID:41306967},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41306967},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_19eb5f8a5da0; sha256 650759f27c4353401781388f9cd42267cf4ce2f35d35959b80cd78d350163fce},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41306967. Agents can read the archived copy with the MCP tool read_document.